Kawasaki‑like Syndrome in COVID‑19

Overview

Kawasaki‑like syndrome, also called Multisystem Inflammatory Syndrome in Children (MIS‑C) when it occurs after SARS‑CoV‑2 infection, is a rare but serious hyperinflammatory condition that shares many features with classic Kawasaki disease (KD). It typically presents 2–6 weeks after an acute COVID‑19 infection, even if the initial illness was mild or asymptomatic. While the classic form of KD primarily affects children under five years of age, MIS‑C can affect a broader age range—from infants to adolescents and, in some cases, young adults.

Key points

• First recognized in April 2020, shortly after the pandemic began.
• Incidence varies by region but is estimated at 1‑2 cases per 100,000 children infected with SARS‑CoV‑2 (CDC, 2023).
• Most cases occur in children aged 5–14, with a slight male predominance (≈60%).
• Higher rates have been reported among Black, Hispanic, and South Asian children, suggesting health‑equity and genetic components.

Symptoms

Kawasaki‑like syndrome presents with a constellation of fever, mucocutaneous changes, gastrointestinal symptoms, and cardiovascular inflammation. The clinical picture can evolve rapidly, so vigilance is essential.

Core criteria (≥ 2 of the following)

• Fever – Persistent high fever (≥ 38.5 °C) lasting ≥ 3 days.
• Rash – Polymorphous, often erythematous, can be maculopapular or morbilliform.
• Conjunctival injection – Bilateral, non‑purulent redness of the eyes.
• Oral mucosal changes – Strawberry tongue, cracked lips, or diffuse erythema of the oral cavity.
• Extremity changes – Swelling or erythema of hands/feet, later followed by desquamation (peeling) of fingers and toes.
• cervical lymphadenopathy – Usually unilateral, ≥ 1.5 cm in diameter.

Additional common features

• Gastrointestinal – Abdominal pain, vomiting, diarrhea (present in > 70% of cases).
• Cardiovascular – Myocarditis, decreased left‑ventricular function, coronary artery dilation/aneurysms, hypotension, or shock.
• Neurologic – Headache, irritability, confusion, or seizures (less common).
• Respiratory – Cough or shortness of breath may coexist, especially if residual COVID‑19 lung involvement is present.
• Laboratory abnormalities – Elevated CRP, ESR, ferritin, D‑dimer, troponin, BNP, neutrophilia, and lymphopenia.

Causes and Risk Factors

The exact pathogenesis remains under investigation. Current evidence points to an abnormal immune response triggered by SARS‑CoV‑2.

• Post‑infectious immune dysregulation – Molecular mimicry and superantigen‑like activity from the viral spike protein may activate T‑cells and cytokine cascades.
• Genetic predisposition – HLA‑type variations (e.g., HLA‑B*58:01) and polymorphisms in immune‑regulatory genes have been linked to higher susceptibility.
• Age – The immune system of children, especially those under 15, appears primed for a hyper‑inflammatory rebound.
• Race/ethnicity – Disproportionately higher incidence in Black, Hispanic, and South Asian populations (CDC, 2023).
• Previous COVID‑19 infection – Most patients have evidence of recent SARS‑CoV‑2 exposure (positive PCR, antigen test, or serology).
• Pre‑existing conditions – Obesity, asthma, or underlying cardiac disease may increase severity, though MIS‑C can affect completely healthy children.

Diagnosis

Because MIS‑C mimics many other illnesses (toxic shock, bacterial sepsis, classic KD), a systematic approach is required.

Clinical assessment

• History of recent COVID‑19 exposure or infection (within 2‑6 weeks).
• Documentation of fever lasting ≥ 3 days and at least 2 of the core Kawasaki criteria.
• Evaluation for organ system involvement (cardiac, gastrointestinal, neurologic).

Laboratory tests

• Inflammatory markers: C‑reactive protein (CRP) > 3 mg/dL, erythrocyte sedimentation rate (ESR) > 40 mm/hr.
• Complete blood count: Neutrophilia, lymphopenia, thrombocytopenia (early) → thrombocytosis (later).
• Cardiac enzymes: Elevated troponin and B‑type natriuretic peptide (BNP) indicating myocarditis.
• Coagulation profile: Elevated D‑dimer, fibrinogen, PT/aPTT abnormalities.
• SARS‑CoV‑2 testing: PCR or antigen test (to rule out active infection) plus serology (IgG) for prior exposure.
• Other cultures: Blood, urine, and respiratory cultures to exclude bacterial sepsis.

Imaging and cardiac evaluation

• Echocardiogram: First‑line to assess left‑ventricular function, pericardial effusion, and coronary artery dimensions.
• Electrocardiogram (ECG): Detect arrhythmias or ST changes.
• Chest X‑ray or CT: Evaluate pulmonary involvement if respiratory symptoms are present.
• MRI/CT angiography: Reserved for persistent coronary abnormalities or aneurysms.

Diagnosis is confirmed when a child meets the CDC/WHO case definition: fever, laboratory evidence of inflammation, multisystem involvement, and recent SARS‑CoV‑2 infection, after excluding alternative diagnoses.

Treatment Options

Prompt treatment reduces the risk of coronary artery aneurysms and other serious outcomes. Management typically occurs in a pediatric intensive care unit (PICU) for close monitoring.

First‑line immunomodulatory therapy

• Intravenous immunoglobulin (IVIG) – 2 g/kg given over 10–12 hours. Reduces fever and inflammation in > 80% of cases (Cleveland Clinic, 2022).
• Aspirin – High‑dose (30‑50 mg/kg/day) until afebrile, then low‑dose (3‑5 mg/kg/day) for antiplatelet effect, especially if coronary changes are present.

Second‑line / adjunctive agents (used when fever persists or cardiac involvement is severe)

• Corticosteroids – Methylprednisolone 1–2 mg/kg/day IV; some protocols start steroids concurrently with IVIG in high‑risk patients.
• Biologic agents –
  • **Infliximab** (TNF‑α blocker) 5‑10 mg/kg IV single dose.
  • **Anakinra** (IL‑1 receptor antagonist) 2–10 mg/kg/day subcutaneously, titrated to response.
  • **Tocilizumab** (IL‑6 receptor blocker) in refractory cases.

Supportive care

• Fluid resuscitation & vasopressors for shock (e.g., norepinephrine, epinephrine).
• Respiratory support – supplemental oxygen, high‑flow nasal cannula, or mechanical ventilation if needed.
• Anticoagulation – low‑molecular‑weight heparin for markedly elevated D‑dimer or documented thrombosis.

Long‑term follow‑up

After discharge, patients need:

• Repeat echocardiograms at 2 weeks, 6 weeks, and 1 year (or per cardiology recommendation).
• Cardiology clinic visits to monitor blood pressure, heart rate, and exercise tolerance.
• Gradual return to physical activity, usually after 4–6 weeks of symptom‑free status and normal cardiac evaluation.

Living with Kawasaki‑like Syndrome in COVID‑19

Even after acute recovery, families may face lingering concerns. Below are practical tips to support the child’s health and well‑being.

• Medication adherence: Keep a medication schedule (IVIG is given in‑hospital, but aspirin and any steroids/biologics at home must be taken exactly as prescribed).
• Monitor vitals at home: Record temperature, heart rate, and blood pressure daily for the first month.
• Balanced nutrition: Emphasize anti‑inflammatory foods—fruits, vegetables, omega‑3‑rich fish, and whole grains. Limit processed sugars and saturated fats.
• Hydration: Encourage regular fluid intake; fever and inflammation increase fluid loss.
• Physical activity: Start with light activities (walking, stretching) and progress based on cardiology clearance.
• School & social life: Coordinate with school nurses to allow gradual reintegration; inform teachers of potential fatigue.
• Psychological support: Anxiety or post‑viral fatigue is common. Access school counseling or pediatric mental‑health services when needed.
• Vaccination: Ensure up‑to‑date immunizations, especially influenza and COVID‑19 boosters, after consulting the pediatrician.

Prevention

Since MIS‑C follows SARS‑CoV‑2 infection, primary prevention focuses on reducing COVID‑19 transmission.

• Adhere to public‑health measures: mask‑wearing in crowded indoor settings, hand hygiene, and physical distancing where community spread is high.
• Complete the recommended COVID‑19 vaccination series for children ≥ 6 months (as of 2024 CDC guidance) and receive booster doses when eligible.
• Prompt testing and isolation of symptomatic individuals or those with known exposure to limit household spread.
• Maintain routine pediatric health visits; discuss any concerns about COVID‑19 exposure with your provider.

Complications

Without timely treatment, Kawasaki‑like syndrome can lead to severe, potentially life‑threatening complications.

• Coronary artery aneurysm or dilation – Occurs in up to 25% of untreated cases; may cause myocardial infarction or chronic ischemia.
• Myocarditis and heart failure – Decreased left‑ventricular ejection fraction, arrhythmias, or cardiogenic shock.
• Thromboembolic events – Deep vein thrombosis, pulmonary embolism, or stroke due to hypercoagulability.
• Renal dysfunction – Acute kidney injury secondary to shock or inflammatory damage.
• Persistent fever and fatigue – Can affect school performance and quality of life for months.
• Psychological impact – Post‑traumatic stress, anxiety, or depression after intensive care admission.

When to Seek Emergency Care

---

**Sources:** CDC, 2023 MIS‑C Data; Mayo Clinic, “Kawasaki disease”; WHO, “Multisystem Inflammatory Syndrome in Children and Adolescents”; Cleveland Clinic, “COVID‑19 and Pediatric Inflammatory Syndromes”; NIH, “Multisystem Inflammatory Syndrome in Children (MIS‑C)”.